Teva Gets Approval for Glyburide/Metformin HCl Tablets

Teva Pharmaceutical has been granted final approval from the FDA for the its abbreviated new drug application for Glyburide and Metformin HCl tablets, 1.25 mg/250 mg, 2.5 mg/500 mg and 5 mg/500 mg.

Shipment of this product is expected to begin shortly.

Teva's Glyburide and Metformin HCl tablets are the AB-rated generic equivalent of Bristol-Myers Squibb's Glucovance tablets, a product indicated as an adjunct to diet and exercise in the treatment of Type 2 diabetes.